PepGen (PEPG) Projected to Post Earnings on Thursday

Key Points

• PepGen (NASDAQ:PEPG) will report Q1 2026 results before the market opens on Thursday, May 14, 2026 with a conference call at 12:30 PM ET; analysts expect ($0.31) EPS
• Shares trade near $1.85 with a market cap of about $127.6M and a 52‑week range of $1.01–$7.80; the stock has mixed analyst coverage (five Buys, one Sell, average rating "Moderate Buy" and average target $11.80) and roughly 58% institutional ownership including large stakes by RA Capital and Viking Global.

PepGen (NASDAQ:PEPG - Get Free Report) is expected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect PepGen to post earnings of ($0.31) per share for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

PepGen (NASDAQ:PEPG - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13. On average, analysts expect PepGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PepGen Stock Down 4.4%

Shares of PEPG stock opened at $1.85 on Thursday. The firm has a market cap of $127.62 million, a price-to-earnings ratio of -0.77 and a beta of 2.01. The company's 50 day moving average is $3.62 and its 200 day moving average is $4.84. PepGen has a 52-week low of $1.01 and a 52-week high of $7.80.

Analyst Ratings Changes

PEPG has been the subject of a number of analyst reports. Wedbush lowered their target price on PepGen from $9.00 to $5.00 and set an "outperform" rating for the company in a report on Tuesday, March 31st. Guggenheim upped their target price on PepGen from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Weiss Ratings restated a "sell (d-)" rating on shares of PepGen in a report on Tuesday, April 21st. Finally, Oppenheimer initiated coverage on PepGen in a report on Wednesday, February 25th. They set an "outperform" rating and a $15.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $11.80.

Institutional Investors Weigh In On PepGen

Several institutional investors have recently bought and sold shares of PEPG. RA Capital Management L.P. boosted its stake in PepGen by 87.7% in the third quarter. RA Capital Management L.P. now owns 20,064,545 shares of the company's stock valued at $92,698,000 after acquiring an additional 9,375,000 shares in the last quarter. Vivo Capital LLC acquired a new stake in PepGen in the third quarter valued at approximately $10,742,000. Viking Global Investors LP boosted its stake in PepGen by 134.9% in the third quarter. Viking Global Investors LP now owns 3,482,434 shares of the company's stock valued at $16,089,000 after acquiring an additional 2,000,000 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in PepGen in the fourth quarter valued at approximately $10,072,000. Finally, Deep Track Capital LP acquired a new stake in PepGen in the third quarter valued at approximately $5,544,000. 58.01% of the stock is currently owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen, Inc NASDAQ: PEPG is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.